Becker's Healthcare June 7, 2022
A company that uses artificial intelligence to discover and develop new drugs has received a $60 million series D investment to grow its robotics offerings.
Insilico Medicine, based in Hong Kong, said it intends to use the capital to expand its global operations and planned initiatives, including a fully automated, AI-directed robotic drug discovery lab and fully robotic biological data factory.
“We plan to continue expanding the breadth of the pipeline...
Today's Sponsors
Today's Sponsor